Sigma Planning Corp reduced its holdings in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 11.0% during the fourth quarter, according to its most recent disclosure with the Securities and ...
BeiGene fleshes out global ambition as Brukinsa surpasses AstraZeneca's Calquence in quarterly sales
On BeiGene’s very first live earnings call, CEO and co-founder John Oyler on Thursday described a “once-in-a-lifetime ...
The pharmaceutical industry is evolving continuously with the advancements in drug discovery with Artificial Intelligence (AI ...
New York State Common Retirement Fund grew its position in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 7.4% during the 4th ...
Learn more about whether AstraZeneca PLC or Intra-Cellular Therapies, Inc. is a better investment based on AAII's A+ Investor ...
AstraZeneca AZN stock has risen 8.6% in the past month, mainly due to mixed fourth-quarter results and a positive update from ...
In this video, Jennifer A. Woyach, MD, discusses results from the AMPLIFY trial, presented at ASH Annual Meeting and Exhibition.The trial evaluated fixed-duration acalabrutinib (Calquence, AstraZeneca ...
Acalabrutinib, made by the drug company AstraZeneca and marketed under the brand name Calquence, works by blocking an enzyme called Bruton’s tyrosine kinase (BTK), which helps cancerous B cells ...
AstraZeneca and Eli Lilly have joined the ... AZ meanwhile is planning to start a trial of its BTK inhibitor Calquence (acalabrutinib), which is currently used to treat various types of blood ...
Calquence (Acalabrutinib): Acerta Pharma/AstraZeneca Calquence (acalbrutinib) is a Bruton’s tyrosine kinase (BTK) inhibitor used in the treatment of Small Lymphocytic Lymphoma (SLL). It is effective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback